ArticleEClinicalMedicine2025

Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial.

Ángeles García-Cazorla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.